SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Rebecca Moore

Senior Scientist

Rebecca Moore

Rebecca works in the adenoviral team developing vaccines targeting infectious diseases and cancer.

She joined Spybiotech at the end of 2021 from the Sir William Dunn School of Pathology, Oxford University, where she spent several years working on HIV-1 biology and vaccine development. Prior to this Rebecca worked at the National Cancer Institute in Frederick, Maryland USA, on the HIV-1 restriction factor APOBEC3G.

Rebecca obtained a PhD in Gene Therapy from Imperial College, London where she worked on adenoviral vectors.

Back to team

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline